“The greatest need we have today in the human cancer problem, except for a universal cure, is a method for detecting cancer before there are any clinical signs or symptoms.”
Sidney Farber, M.D.
Father of modern chemotherapy
pioneering the detection of early cancer
Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. Incubated within Flagship Pioneering for three years before launching in 2021, Harbinger combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test.
A harbinger is a “forerunner, that which precedes and gives notice of the coming of another.” We not only are working to identify the harbinger – the biological programs present in the earliest forms of cancer – but seek to be the harbinger, to be the forerunner which will usher in the future of healthcare.
At Harbinger, we intend to lead in shaping this future – creating a proactive paradigm so that people can live cancer-free for longer, adding years to life and life to years. We envision a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies.
Our answer to the problem of late cancer detection and unacceptable patient prognoses starts with our proprietary solutions for the future of cancer pre-emption. Beginning with blood-based tests, we will enable cancer detection before it is visible. By identifying biological programs rooted in cancer's origins, we can enable identification of early stage and pre-disease. Through this new pathway for cancer diagnosis and early therapeutic interventions, Harbinger Health has the potential to fundamentally change cancer care, for everyone.
Margo Georgiadis is a CEO-Partner at Flagship Pioneering and Co-Founder and CEO of Montai Health. In these roles, Margo brings extensive expertise in technological innovation and high-performance business transformation and leverages her artificial intelligence and machine learning experience to advance biotech innovation. Working with Flagship CEO and Founder Noubar Afeyan and Lord Ara Darzi, she plays an instrumental role in Flagship’s efforts to scale its Preemptive Medicine & Health Initiative and develop new companies aimed at deterring or delaying the onset of disease, improve health outcomes for consumers, corporations, and countries.
Margo is an experienced CEO and company builder who has dedicated her career to transforming products and services with data and technology to empower consumers to live better lives, and to deliver outsized growth and returns for investors. Most recently, she served as an Endurance Partner at venture catalyst firm General Catalyst, where she focused on building next-generation healthcare platforms that improve clinical outcomes while making healthcare more consumer-centric, accessible and affordable. Previously, she served as President and CEO of Ancestry where she brought together content, science, and technology to transform Ancestry into the undisputed global leader in family history and consumer genomics. Under her leadership, the company scaled to over 3.6M subscribers, doubled its genomics network to over 20M customers and delivered over $1B in subscription revenue with record setting profitability and cash flow.
Margo also spent nine years at Google as President of Americas and Vice President of Global Operations, leading the hyper scaling of Google’s commercial operations and advertising sales across all digital solutions including search, mobile, video, shopping, local and commerce, and platforms. Her other operating roles include serving as the CEO of Mattel, Inc., the COO of Groupon, EVP of US Card Services and CMO at Discover Financial Services, and as a partner at McKinsey and Company.
Beyond her operating roles, Margo is an experienced investor at the intersection of health and technology and has helped to scale multiple successful platform companies as an Endurance Partner at General Catalyst and a Managing Partner at Synetro Group.
Margo has received multiple awards for her business and community leadership including the Forbes “Excellence Award in Innovation,” Chicago Innovation’s “Visionary Award,” the Eastman Medal from the University of Rochester, Executive of the Year in Utah, and was named to Crain’s “Most Powerful Women in Business” and Fortune’s “50 Most Powerful Women in Business” lists.
Margo serves on multiple Boards including McDonald’s, Applovin, Ro, Handshake, the Parker Institute for Cancer Immunotherapy and People’s Health Clinic. She earned a BA in Economics from Harvard College and an MBA from Harvard Business School.
our leadership team
our board of directors
Director, Social & Behavioral Sciences, Community Engagement
Operation Warp Speed
Professor, Department of Gastrointestical Medical Oncology
Chair Department of Investigational Cancer Therapeutics
Chief Quality Officer
Board member, Kaiser Foundation